Top companies

RELIANCE - 1257.5 (0%) BAJFINANCE - 1034.5 (0%) ITC - 259.85 (0%) BPCL - 304.5 (0%) ONGC - 232.5 (0%) AXISBANK - 1246 (0%) INDUSINDBK - 978.2 (0%) TATASTEEL - 183 (0%) HINDUNILVR - 1927 (0%) MARUTI - 12400 (0%) HDFCBANK - 708.25 (0%) HEROMOTOCO - 5221.5 (0%) TITAN - 5009.5 (0%) ICICIBANK - 1379.3 (0%) ASIANPAINT - 2472.5 (0%) SBIN - 995.7 (0%) KOTAKBANK - 419 (0%) BAJAJFINSV - 1913.5 (0%) WIPRO - 167.4 (0%) COALINDIA - 426.4 (0%) BHARTIARTL - 1831.1 (0%) TCS - 2200.8 (0%)
TRENDING #Asian Paints Limited711 #ITC Limited613 #Axis Bank Limited533 #HDFC Bank Limited283

Why Cardiologists Are Fighting the DGHS Ban on Reusing Medical Devices

16 Nov , 2026   By : Shambhavi Mishra


Why Cardiologists Are Fighting the DGHS Ban on Reusing Medical Devices

? Quick Take: The Cardiological Society of India's Kerala chapter wants the DGHS to reconsider its ban on reusing select single-use medical devices. For everyday patients, this regulatory clash dictates whether life-saving angioplasties remain financially viable or push households deeper into debt.

For millions of Indian households facing the crushing expense of cardiovascular disease, hospital bills are a constant source of anxiety. When the Directorate General of Health Services (DGHS) implements a blanket ban on the re-use of single-use medical devices, patient advocacy groups and medical professionals take notice. The Cardiological Society of India's Kerala chapter has stepped up, arguing that rigid restrictions are pricing ordinary patients out of modern cardiac care.

The Real Cost of Single-Use Mandates

Advanced interventional cardiology relies heavily on specialized hardware like catheters, guidewires, and balloons. Many of these tools are engineered with durable materials capable of safely enduring multiple sterilizations and procedures under strict protocols. When hospitals are forced to discard them after a single use, the procurement overhead translates directly into inflated procedure packages.

India's private healthcare market operates on tight margins for volume, but high-end consumables command exorbitant price tags. Stripping away the option to re-sterilize scientifically proven devices removes a vital financial cushion for uninsured patients. The debate is no longer just about clinical guidelines; it is about who shoulders the burden of ballooning healthcare inflation.

Balancing Patient Safety With Economic Realities

Regulatory bodies face a difficult balancing act. Ensuring absolute sterility and zero cross-contamination risk is non-negotiable in cardiac catheterization labs. Yet, medical innovation and rigorous clinical protocols have evolved to make controlled reprocessing a standard practice in several advanced economies.

Cardiologists argue that a blanket ban throws the baby out with the bathwater. Instead of prohibiting the practice outright, critics of the DGHS order suggest establishing a robust framework for certified reprocessing. Such a move would maintain stringent safety audits while preventing unnecessary medical waste and runaway patient bills.

What Should Investors Do Now?

  • Track Healthcare Policy Shifts: Keep a close eye on regulatory updates from the Ministry of Health and Family Welfare regarding medical device pricing and re-use guidelines.
  • Analyze Hospital Margins: Evaluate how listed hospital chains manage consumable costs, as any policy reversal could impact their operating margins and package pricing structures.
  • Assess Insurance Exposure: Rising procedural costs drive up health insurance claims, making it essential to review policy coverage limits for cardiac interventions.

Source Attribution: Originally reported by hindu-national (https://www.thehindu.com/news/national/kerala/cardiologists-seek-review-of-dghs-order-banning-re-use-of-single-use-medical-devices-to-reduce-angioplasty-costs/article71683041.ece).

Disclaimer: The financial, market, and corporate developments published above are reported for informational and educational purposes only. GrowMudra does not provide investment advice or stock recommendations. Readers are strongly advised to consult a SEBI-registered financial advisor before making investment decisions.

0 Comment


LEAVE A COMMENT


Growmudra © 2026 all right reserved

Partner With Us